TREM1 and periodontitis: The major novel finding of this in vivo study is that local (gingival) injection of a TREM-1 blocking peptide, namely LP17, substantially reduced the RANKL/OPG osteoclastogenic ratio and alveolar bone loss, thus providing preclinical support for a new therapeutic target for periodontitis.